<DOC>
	<DOCNO>NCT00305448</DOCNO>
	<brief_summary>This study ass relationship fulvestrant dose efficacy , determine dose regimen second line therapy Japanese postmenopausal woman oestrogen receptor positive advanced breast cancer .</brief_summary>
	<brief_title>A Clinical Trial Compare Efficacy Tolerability Fulvestrant 250mg , 250mg ( Plus 250mg Loading Regimen ) 500mg</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Breast Cancer continue grow receive treatment antiestrogen hormonal treatment tamoxifen aromatase inhibitor Requiring hormonal treatment Postmenopausal woman define woman stop menstrual period Treatment one previous regimen systemic anticancer therapy endocrine therapy advance breast cancer Treatment one previous regimen endocrine therapy advance breast cancer An exist serious disease , illness , condition prevent participation compliance study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>